E Haddad, J J Mazeron, M Martin, L Vergnes, B Brun, P Piedbois, A Coste, G Lelievre, R Peynegre, J P Le Bourgeois
From April 1987 to October 1992, 67 patients with inoperable squamous cell carcinoma of the head and neck region were included in a randomized trial. All patients had induction chemotherapy with cisplatin (100 mg/m2, D1) and fluorouracil (1 g/m2, from D1 to D5) every three weeks for a total of three cycles. Patients were randomized to concurrent external radiation therapy (70 Gy/39 fractions/8 weeks) and chemotherapy with cisplatin (50 mg/m2 in short infusion, D1, D15, D29, D43) and fluorouracil (5 mg/kg, intra-muscular, every Monday, Wednesday and Friday) (experimental group) versus radiotherapy alone with the same modalities (control group). The followup for living patients was 14 to 60 months with a median of 42 months. Analysis of preliminary results has shown that: 1) early and late side effects are similar in both groups; 2) after completion of treatment, the percentage of patients in complete remission was 71% (20/28) in the experimental group and 43% (12/28) in the control group; this difference was statistically significant among non responders to induction chemotherapy (1/15 versus 13/20, P = 0.001), but non significant among responders (11/13 versus 7/8) and 3) there were no differences between both randomized groups in term of 3-year overall survival and of 3-year loco-regional control. Results are discussed taking into account a review of literature.
1987年4月至1992年10月，67例头颈部不能手术的鳞状细胞癌患者被纳入一项随机试验。所有患者均采用顺铂(100 mg/m2, D1)和氟尿嘧啶(1 g/m2, D1 ~ D5)诱导化疗，每3周1次，共3个周期。患者随机分为同步外放疗(70 Gy/39次/8周)和顺铂(50 mg/m2，短时间输注，D1、D15、D29、D43)和氟尿嘧啶(5 mg/kg，肌肉内注射，每周一、三、五)化疗组(实验组)和相同方式的单独放疗组(对照组)。在世患者随访14 ~ 60个月，中位随访42个月。初步结果分析表明:1)两组患者早期和晚期副作用相似;2)治疗结束后，实验组患者完全缓解率为71%(20/28)，对照组为43% (12/28);在诱导化疗无应答者中，差异有统计学意义(1/15 vs 13/20, P = 0.001)，但在应答者中差异无统计学意义(11/13 vs 7/8)，在3年总生存期和3年局部区域对照中，两个随机分组之间无差异。讨论的结果考虑到文献综述。
{"title":"[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].","authors":"E Haddad, J J Mazeron, M Martin, L Vergnes, B Brun, P Piedbois, A Coste, G Lelievre, R Peynegre, J P Le Bourgeois","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>From April 1987 to October 1992, 67 patients with inoperable squamous cell carcinoma of the head and neck region were included in a randomized trial. All patients had induction chemotherapy with cisplatin (100 mg/m2, D1) and fluorouracil (1 g/m2, from D1 to D5) every three weeks for a total of three cycles. Patients were randomized to concurrent external radiation therapy (70 Gy/39 fractions/8 weeks) and chemotherapy with cisplatin (50 mg/m2 in short infusion, D1, D15, D29, D43) and fluorouracil (5 mg/kg, intra-muscular, every Monday, Wednesday and Friday) (experimental group) versus radiotherapy alone with the same modalities (control group). The followup for living patients was 14 to 60 months with a median of 42 months. Analysis of preliminary results has shown that: 1) early and late side effects are similar in both groups; 2) after completion of treatment, the percentage of patients in complete remission was 71% (20/28) in the experimental group and 43% (12/28) in the control group; this difference was statistically significant among non responders to induction chemotherapy (1/15 versus 13/20, P = 0.001), but non significant among responders (11/13 versus 7/8) and 3) there were no differences between both randomized groups in term of 3-year overall survival and of 3-year loco-regional control. Results are discussed taking into account a review of literature.</p>","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 2","pages":"97-103"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19662462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1996-01-01DOI: 10.1016/0924-4212(96)84879-1
G. Wolber , Y. Guibbaud , R. Dollo
Personal neutron dosimetry in nuclear power plants is one of the hardest to achieve because there is no nuclear reaction that is both efficient and which ensures a suitable discrimination between 50 keV to 2 MeV fast neutrons and gamma photons. Neutron doses being low, the method used until now has been based on ambient dosimetry and the spent time in exposed areas. The advent of bubble detectors meets our immediate requirements until the direct reading electronic neutron dosimeter, which is still at the feasability research stage, can be utilized.
La dosimétrie individuelle des neutrons dans les centrales nucléaires est une des plus difficiles à réaliser car il n ‘y a pas de reaction nucléaire à la fois efficace et assurant une bonne discrimination entre les neutrons rapides de 50 keV à 2 MeV et les photons gamma. Les doses neutroniques étant faibles, la méthode utilisée jusqu’à présent a été basée sur la dosimétrie ambiante et le temps de sejour dans les zones exposées. La commercialisation des dosimètres à bulles satisfait nos besoins immédiats en attendant le dosimètre électronique à lecture directe, encore à l’etude de faisabilité.
{"title":"Neutron dosimetry in French nuclear power plants. Problems and their solutions in 1995","authors":"G. Wolber , Y. Guibbaud , R. Dollo","doi":"10.1016/0924-4212(96)84879-1","DOIUrl":"10.1016/0924-4212(96)84879-1","url":null,"abstract":"<div><p>Personal neutron dosimetry in nuclear power plants is one of the hardest to achieve because there is no nuclear reaction that is both efficient and which ensures a suitable discrimination between 50 keV to 2 MeV fast neutrons and gamma photons. Neutron doses being low, the method used until now has been based on ambient dosimetry and the spent time in exposed areas. The advent of bubble detectors meets our immediate requirements until the direct reading electronic neutron dosimeter, which is still at the feasability research stage, can be utilized.</p></div><div><p>La dosimétrie individuelle des neutrons dans les centrales nucléaires est une des plus difficiles à réaliser car il n ‘y a pas de reaction nucléaire à la fois efficace et assurant une bonne discrimination entre les neutrons rapides de 50 keV à 2 MeV et les photons gamma. Les doses neutroniques étant faibles, la méthode utilisée jusqu’à présent a été basée sur la dosimétrie ambiante et le temps de sejour dans les zones exposées. La commercialisation des dosimètres à bulles satisfait nos besoins immédiats en attendant le dosimètre électronique à lecture directe, encore à l’etude de faisabilité.</p></div>","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 ","pages":"Pages 19s-26s"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0924-4212(96)84879-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19912790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1996-01-01DOI: 10.1016/0924-4212(96)84910-3
D. Gabel
For successful application of boron neutron capture therapy to the treatment of cancer, selective accumulation of boron is required. This can be achieved by the preparation of suitable substances, which must contain boron and at the same time accumulate or be retained in tumor tissue. The radiobiological rationale for selection of suitable compounds is disaussed. Examples of useful new compounds are given for which boronated analogues exist.
Une concentration sélective des composés borés au niveau des cellules cancéreuses est indispensable pour assurer le succès de la thérapie par capture de neutrons thermiques. Nous passons en revue les principales classes de composés borés susceptibles d’être utilisées en clinique et nous discutons les critères radiobiologiques permettant de les sélectionner. Un certain nombre de nouveaux composés sont présentés pour lesquels il existe des analogues bores.
For成功应用of boron中子俘获疗法去治疗癌症,is set of boron积累艾滋。这可以通过制备适当的物质来实现，这些物质必须含有硼，同时在肿瘤组织中积累或保留。选择合适化合物的放射生物学原理已被讨论。实例are a propos new化合物来exist for which boronated类似。在癌细胞水平上选择性地浓缩硼化合物对热中子捕获治疗的成功至关重要。我们回顾了可用于临床的硼化合物的主要类别，并讨论了选择它们的放射生物学标准。介绍了一些存在bores类似物的新化合物。
{"title":"Progress in the field of compounds for boron neutron capture therapy","authors":"D. Gabel","doi":"10.1016/0924-4212(96)84910-3","DOIUrl":"10.1016/0924-4212(96)84910-3","url":null,"abstract":"<div><p>For successful application of boron neutron capture therapy to the treatment of cancer, selective accumulation of boron is required. This can be achieved by the preparation of suitable substances, which must contain boron and at the same time accumulate or be retained in tumor tissue. The radiobiological rationale for selection of suitable compounds is disaussed. Examples of useful new compounds are given for which boronated analogues exist.</p></div><div><p>Une concentration sélective des composés borés au niveau des cellules cancéreuses est indispensable pour assurer le succès de la thérapie par capture de neutrons thermiques. Nous passons en revue les principales classes de composés borés susceptibles d’être utilisées en clinique et nous discutons les critères radiobiologiques permettant de les sélectionner. Un certain nombre de nouveaux composés sont présentés pour lesquels il existe des analogues bores.</p></div>","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 ","pages":"Pages 186s-190s"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0924-4212(96)84910-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19912796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1996-01-01DOI: 10.1016/0924-4212(96)84902-4
N. Iborra-Brassart , S. Vynckier , J. Herault , P. Chauvel
Neulron dosimetry intercomparison studies have been undertaken at the Nice neutrontherapy facility with the staff at Louvain-la-Neuve which has had wide experience in both dosimetric and radiobiological intercomparisons. Tissue equivalent (TE) ionization chambers were first calibrated in 60Co beams and then exposed in the neulron beam at different depths in a water phantom; the largest difference observed in neutron beam measurements with all the chambers tested was 0.89%, and most of them agreed to within less than 0.5%. The gamma component at four depths was derived from measurements with Geiger-Müller counters; the results obtained with the two counters (Nice and Louvain-Ia-Neuve), expressed as a percentage of the total dose (neutron + gamma), agreed to within less than 0.03% and the value increased from 1.4 to 4.2% between 2 and 20 cm in depth.
Une intercomparaison dosimétrique et radiobiologique a été réalisée sous le faisceau de neutrons à Nice avec l’équipe de Louvain-la-Neuve qui a participé à toutes les intercomparaisons sous les différents faisceaux de neutrons en Europe, en Afrique et aux États-Unis. Les chambres d’ionisation, à tissu équivalent (TE) ont d’abord été étalonnées sous faisceau de 60Co puis des mesures ont été réalisées à différentes profondeurs, dans un fantôme d’eau, sous le faisceau de neutrons; les résultats obtenus diffèrent au maximum de 0,89% entre toutes les chambres et quelles que soient les profondeurs; l’écart entre la plupart des mesures est inférieur à 0,5%. La composante gamma a été étudiée à quatre profondeurs différentes avec des compteurs Geiger-Muller; les résultats sont exprimés en pourcentage de la dose totale (neutron + gamma). Les valeurs obtenues avec les deux compteurs ne diffèrent que par 0,03% au maximum et la composante gamma augmente de 1,4% à 4,2% entre 2 et 20 cm de profondeur.
已在尼斯中子治疗设施与在剂量学和放射生物学相互比较方面具有广泛经验的卢万-拉-纽夫工作人员进行了中子剂量学相互比较研究。组织当量(TE)电离室首先在60Co光束中校准，然后在水模体中不同深度的中子束中暴露;中子束测量结果与所有实验室的最大差异为0.89%，大多数实验室的差异都在0.5%以内。四个深度的伽马分量由盖格-迈勒计数器测量得出;两个计数器(Nice和Louvain-Ia-Neuve)得到的结果，以总剂量(中子+伽马)的百分比表示，同意在小于0.03%的范围内，该值在2至20厘米深度从1.4增加到4.2%。一个相互比较的数据，例如，与放射生物学有关的数据，例如，与其他数据有关的数据，例如，与其他数据有关的数据，例如，与其他数据有关的数据，例如，与其他数据有关的数据，例如，与其他数据有关的数据，例如，欧洲，非洲等États-Unis。电离室，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)，组织等效(TE)三种不同类型的人有不同的生活方式，最多不超过0.89%的人有不同的生活方式;L ' samatatentre la plupart des measures est infacrieur 0,5%。格格-穆勒(Geiger-Muller);在实验中，雷蒙斯的总剂量(中子+ γ)占总剂量的百分比。在不同的条件下，双计算机的平均值为0.03%，最大值为0.03%，复合伽马增强值为1.4%，最大值为4.2%，深度为2厘米，深度为20厘米。
{"title":"The Nice high-energy neutron facility: dosimetry intercomparisons","authors":"N. Iborra-Brassart , S. Vynckier , J. Herault , P. Chauvel","doi":"10.1016/0924-4212(96)84902-4","DOIUrl":"10.1016/0924-4212(96)84902-4","url":null,"abstract":"<div><p>Neulron dosimetry intercomparison studies have been undertaken at the Nice neutrontherapy facility with the staff at Louvain-la-Neuve which has had wide experience in both dosimetric and radiobiological intercomparisons. Tissue equivalent (TE) ionization chambers were first calibrated in <sup>60</sup>Co beams and then exposed in the neulron beam at different depths in a water phantom; the largest difference observed in neutron beam measurements with all the chambers tested was 0.89%, and most of them agreed to within less than 0.5%. The gamma component at four depths was derived from measurements with Geiger-Müller counters; the results obtained with the two counters (Nice and Louvain-Ia-Neuve), expressed as a percentage of the total dose (neutron + gamma), agreed to within less than 0.03% and the value increased from 1.4 to 4.2% between 2 and 20 cm in depth.</p></div><div><p>Une intercomparaison dosimétrique et radiobiologique a été réalisée sous le faisceau de neutrons à Nice avec l’équipe de Louvain-la-Neuve qui a participé à toutes les intercomparaisons sous les différents faisceaux de neutrons en Europe, en Afrique et aux États-Unis. Les chambres d’ionisation, à tissu équivalent (TE) ont d’abord été étalonnées sous faisceau de <sup>60</sup>Co puis des mesures ont été réalisées à différentes profondeurs, dans un fantôme d’eau, sous le faisceau de neutrons; les résultats obtenus diffèrent au maximum de 0,89% entre toutes les chambres et quelles que soient les profondeurs; l’écart entre la plupart des mesures est inférieur à 0,5%. La composante gamma a été étudiée à quatre profondeurs différentes avec des compteurs Geiger-Muller; les résultats sont exprimés en pourcentage de la dose totale (neutron + gamma). Les valeurs obtenues avec les deux compteurs ne diffèrent que par 0,03% au maximum et la composante gamma augmente de 1,4% à 4,2% entre 2 et 20<!--> <!-->cm de profondeur.</p></div>","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 ","pages":"Pages 153s-156s"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0924-4212(96)84902-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19914160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Portal imaging: the legal point of view].","authors":"P Martin","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"414-7"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20034141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Non-Hodgkin's lymphoma in adults. Therapeutic strategy].","authors":"J P Le Bourgeois, F Reyes","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"258-64"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20034205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Treatment of bone metastases].","authors":"G Kantor, J M Simon","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"275-6"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20034208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Radiotherapy of bone metastases. A review of the literature].","authors":"J M Simon","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"290-8"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20034211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J C Horiot, P Bontemps, A C Begg, R Le Fur, W Van den Bogaert, M Bolla, T N'Guyen, D Van den Weijngaert, J Bernier, A Lusinchi, D Stuschke, D Lopez Torrecilla, B Jancar, L Collette, M Van Glabbeke, M Pierart
{"title":"[Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice].","authors":"J C Horiot, P Bontemps, A C Begg, R Le Fur, W Van den Bogaert, M Bolla, T N'Guyen, D Van den Weijngaert, J Bernier, A Lusinchi, D Stuschke, D Lopez Torrecilla, B Jancar, L Collette, M Van Glabbeke, M Pierart","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"314-20"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20034214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J Lescrainier, M Grelot, C Boutinaud, H Bouscayrol, I Champeaux, C Ginestet
{"title":"[Quality control in electronic portal imaging devices. Commission Imagerie, Société française des physiciens d'hôpital].","authors":"J Lescrainier, M Grelot, C Boutinaud, H Bouscayrol, I Champeaux, C Ginestet","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":79321,"journal":{"name":"Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique","volume":"83 4","pages":"409-13"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20034228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号